Drug Profile
Gallium-68-THP PSMA
Alternative Names: (68)Ga-THP-PSMA; 68Ga-THP-PSMA; [68Ga]THP-PSMA PET/CT; [68Ga]Tris(hydroxypyridinone)(THP)-PSMA; Ga-68-THP-PSMA; GalliProst; Gallium-68 tris-hydroxypyridinone prostate specific membrane antigen; THG-001Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Kings College London
- Developer Ariceum Therapeutics; Peter MacCallum Cancer Centre
- Class Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Prostate cancer